Advertisement
Research Article

I1 Imidazoline Receptor: Novel Potential Cytoprotective Target of TVP1022, the S-Enantiomer of Rasagiline

  • Yaron D. Barac equal contributor,

    equal contributor Contributed equally to this work with: Yaron D. Barac, Orit Bar-Am, Esti Liani, Tamar Amit

    Affiliation: Department of Physiology and Biophysics, Faculty of Medicine, Technion, Haifa, Israel

    X
  • Orit Bar-Am equal contributor,

    equal contributor Contributed equally to this work with: Yaron D. Barac, Orit Bar-Am, Esti Liani, Tamar Amit

    Affiliation: Eve Topf and National Parkinson Foundation Center For Neurodegenerative Diseases Research and Department of Pharmacology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

    X
  • Esti Liani equal contributor,

    equal contributor Contributed equally to this work with: Yaron D. Barac, Orit Bar-Am, Esti Liani, Tamar Amit

    Affiliation: Department of Physiology and Biophysics, Faculty of Medicine, Technion, Haifa, Israel

    X
  • Tamar Amit equal contributor,

    equal contributor Contributed equally to this work with: Yaron D. Barac, Orit Bar-Am, Esti Liani, Tamar Amit

    Affiliation: Eve Topf and National Parkinson Foundation Center For Neurodegenerative Diseases Research and Department of Pharmacology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

    X
  • Luba Frolov,

    Affiliation: Department of Physiology and Biophysics, Faculty of Medicine, Technion, Haifa, Israel

    X
  • Elena Ovcharenko,

    Affiliation: Department of Physiology and Biophysics, Faculty of Medicine, Technion, Haifa, Israel

    X
  • Itzchak Angel,

    Affiliation: A.P.C.T. Ltd., Ness-Ziona, Israel

    X
  • Moussa B. H. Youdim,

    Affiliation: Eve Topf and National Parkinson Foundation Center For Neurodegenerative Diseases Research and Department of Pharmacology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

    X
  • Ofer Binah mail

    binah@tx.technion.ac.il

    Affiliation: Department of Physiology and Biophysics, Faculty of Medicine, Technion, Haifa, Israel

    X
  • Published: November 15, 2012
  • DOI: 10.1371/journal.pone.0047890

About the Authors

Yaron D. Barac, Esti Liani, Luba Frolov, Elena Ovcharenko, Ofer Binah
Department of Physiology and Biophysics, Faculty of Medicine, Technion, Haifa, Israel
Orit Bar-Am, Tamar Amit, Moussa B. H. Youdim
Eve Topf and National Parkinson Foundation Center For Neurodegenerative Diseases Research and Department of Pharmacology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Itzchak Angel
A.P.C.T. Ltd., Ness-Ziona, Israel

Corresponding Author

Email: binah@tx.technion.ac.il

Competing Interests

The authors have read the journal's policy and have the following conflicts: TVP1022 is in the development process of becoming a novel cardioprotective drug. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. IA is a one man consulting company A.P.C.T. Ltd, that was hired to help the authors conduct the TV0122 profiling.

Author Contributions

Conceived and designed the experiments: YDB OBA EL TA MBHY OB. Performed the experiments: OBA EL LF EO. Analyzed the data: OBA EL TA IA. Wrote the paper: YDB OBA TA OB.